Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00942084 · ClinicalTrials.gov registry record · Phase 1
A Study to Describe the Pharmacokinetics of Acyclovir in Premature Infants (PTN_Acyclo)
A Phase 1 study, sponsored by Phillip Brian Smith.
- Completed
- Registry status
- Phase 1
- Development phase
- 32
- Enrollment target
NCT00942084: Completed Phase 1 study, sponsored by Phillip Brian Smith.
NCT00942084 is a Phase 1 study that has completed, run by Phillip Brian Smith. The registered enrollment target is 32 participants. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT00942084, a Phase 1 study, has completed, sponsored by Phillip Brian Smith.
- COMPLETED
- Registry status
- Phase 1
- Development phase
- 32 participants
- Enrollment target
Study Summary
Acyclovir is a drug used to treat herpes simplex virus (HSV) infections in babies. Appropriate dosing of acyclovir is known for adults and children but acyclovir has not been adequately studied in full-term or premature neonates. HSV is a very serious infection in babies \<6 months of age and often results in death or profound mental retardation. HSV leads to profound mental retardation in young infants because the virus attacks the central nervous system. The investigators hypothesize that the currently recommended dose of acyclovir is inadequate to produce adequate blood levels to combat herpes simplex infection. The investigators propose to study acyclovir levels in the blood of babies who are placed on acyclovir to treat a suspected HSV infection. This will allow them to determine the appropriate dose in premature infants. This is an unmet public health need because it is likely that the drug behaves differently in premature infants than it does in term infants and older children. Premature babies have more body water and less body tissue. Their kidneys are more immature and do not function as well as full term infants. Premature neonates are also at the greatest risk from herpes infection because they have poorly functioning immature immune systems. Early and appropriate treatment with acyclovir has resulted in improved outcome in term infants.
Interventions
- DRUG Acyclovir
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 32 participants |
| Start Date | 2011-09 |
| Est. Completion | 2012-06 |
| Phase | Phase 1 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT00942084
The ClinicalTrials.gov registry entry for NCT00942084 describes a study currently listed as completed, categorized as Phase 1. The registered enrollment target is 32 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Phillip Brian Smith, which has 6 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 1 intervention - of which Acyclovir is the first listed.
NCT00942084 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT00942084 about?
NCT00942084 is a clinical study titled "A Study to Describe the Pharmacokinetics of Acyclovir in Premature Infants (PTN_Acyclo)". Acyclovir is a drug used to treat herpes simplex virus (HSV) infections in babies. Appropriate dosing of acyclovir is known for adults and children but acyclovir has not been adequately studied in full-term or premature neonates. HSV is a very serious infection in babies \<6 months of age and often ...
What is the current status of trial NCT00942084?
This trial is currently completed. It is a Phase 1 study. The enrollment target is 32 participants. The study started on 2011-09. Estimated completion is 2012-06.
What interventions are being tested in trial NCT00942084?
The interventions under investigation include: Acyclovir (DRUG).
Who is sponsoring clinical trial NCT00942084?
This trial is sponsored by Phillip Brian Smith, which has 6 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, the data changelog, or report a data error.